胰高血糖素样肽-1在帕金森病“肠-脑轴”中的作用研究进展

doi:10.3969/j.issn.1004-583X.2023.09.015

摘要/Abstract

摘要：

帕金森病(PD)是中老年时期常见的神经退行性疾病之一。PD患者出现肠道炎症、便秘等胃肠道症状可能早于运动障碍。Braak假说假设异常的α-突触核蛋白在肠道中开始积累,并通过迷走神经以类似朊病毒的方式传至大脑,且这一观点得到病理生理学证据的支持。PD中“肠-脑轴”的关联在于代谢、免疫和炎症等相关机制,通过探讨其中机制可能成为治疗PD的新思路。胰高血糖素样肽-1(GLP-1)作为研究较多的代谢物质之一,广泛参与在神经退行性病变中。本文对GLP-1在PD“肠-脑轴”中的作用进行综述,以期为PD提供新的诊疗及研究思路。

中图分类号:

R742.5

周正新, 梁秋雄, 陈江瑛. 胰高血糖素样肽-1在帕金森病“肠-脑轴”中的作用研究进展[J]. 临床荟萃, 2023, 38(9): 855-858.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2023.09.015

https://huicui.hebmu.edu.cn/CN/Y2023/V38/I9/855

参考文献 29

[1]	Nguyen PH, Ramamoorthy A, Sahoo BR, et al. Amyloid oligomers: A joint experimental/computational perspective on alzheimer's disease, parkinson's disease, type ii diabetes, and amyotrophic lateral sclerosis[J]. Chem Rev, 2021, 121(4):2545-2647. doi: 10.1021/acs.chemrev.0c01122 pmid: 33543942
[2]	Zhang LY, Jin QQ, Hölscher C, et al. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat parkinson model[J]. Neural Regen Res, 2021, 16(8):1660-1670. doi: 10.4103/1673-5374.303045 URL
[3]	Kopp KO, Glotfelty EJ, Li Y, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment[J]. Pharmacol Res, 2022, 186:106550. doi: 10.1016/j.phrs.2022.106550 URL
[4]	Manfready RA, Forsyth CB, Voigt RM, et al. Gut-brain communication in parkinson's disease: Enteroendocrine regulation by GLP-1[J]. Curr Neurol Neurosci Rep, 2022, 22(7):335-342. doi: 10.1007/s11910-022-01196-5
[5]	Liu W, Lim KL, Tan EK. Intestine-derived α-synuclein initiates and aggravates pathogenesis of parkinson's disease in Drosophila[J]. Transl Neurodegener, 2022, 11(1):44. doi: 10.1186/s40035-022-00318-w pmid: 36253844
[6]	Rodrigues PV, de Godoy JVP, Bosque BP, et al. Transcellular propagation of fibrillar α-synuclein from enteroendocrine to neuronal cells requires cell-to-cell contact and is Rab35-dependent[J]. Sci Rep, 2022, 12(1):4168. doi: 10.1038/s41598-022-08076-5 pmid: 35264710
[7]	Braak H, Rüb U, Gai WP, et al. Idiopathic parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen[J]. J Neural Transm (Vienna), 2003, 110(5):517-536.
[8]	Borghammer P. How does parkinson's disease begin? perspectives on neuroanatomical pathways, prions, and histology[J]. Mov Disord, 2018, 33(1):48-57. doi: 10.1002/mds.v33.1 URL
[9]	Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease[J]. Movement Disorders, 2012, 27(6):709-715. doi: 10.1002/mds.23838 pmid: 21766334
[10]	Friedland RP, Chapman MR. The role of microbial amyloid in neurodegeneration[J]. PLoS Pathog, 2017, 13(12):e1006654.
[11]	Dumitrescu L, Marta D, Dănău A, et al. Serum and fecal markers of intestinal inflammation and intestinal barrier permeability are elevated in parkinson's disease[J]. Front Neurosci. 2021, 18(15):689723.
[12]	Sampson T, Debelius J, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson's disease[J]. Cell, 2016, 167(6):1469-1480,e12. doi: S0092-8674(16)31590-2 pmid: 27912057
[13]	Joers V, Masilamoni G, Kempf D, et al. Microglia, inflammation and gut microbiota responses in a progressive monkey model of parkinson's disease: A case series[J]. Neurobiol Dis, 2020, 144:105027. doi: 10.1016/j.nbd.2020.105027 URL
[14]	Abdel-Haq R, Schlachetzki JCM, Glass CK, et al. Microbiome-microglia connections via the gut-brain axis[J]. J Exp Med, 2019, 216(1):41-59. doi: 10.1084/jem.20180794
[15]	Nishiwaki H, Hamaguchi T, Ito M, et al. Short-chain fatty acid-producing gut microbiota is decreased in parkinson's disease but not in rapid-eye-movement sleep behavior disorder[J]. mSystems, 2020, 5(6):e00797-e007920.
[16]	Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication[J]. Front Endocrinol (Lausanne), 2020, 31(11):25.
[17]	Ducastel S, Touche V, Trabelsi MS, et al. The nuclear receptor FXR inhibits glucagon-like peptide-1 secretion in response to microbiota-derived short-chain fatty acids[J]. Sci Rep, 2020, 10(1):174. doi: 10.1038/s41598-019-56743-x pmid: 31932631
[18]	Uyar M, Lezius S, Buhmann C, et al. Diabetes, glycated hemoglobin (hba1c), and neuroaxonal damage in parkinson's disease (MARK-PD study)[J]. Mov Disord, 2022, 37(6):1299-1304. doi: 10.1002/mds.v37.6 URL
[19]	Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1[J]. Cell Metab, 2018, 27(4):740-756. doi: S1550-4131(18)30179-7 pmid: 29617641
[20]	Elabi OF, Davies JS, Lane EL. L-dopa-dependent effects of GLP-1R agonists on the survival of dopaminergic cells transplanted into a rat model of parkinson disease[J]. Int J Mol Sci, 2021, 22(22):12346. doi: 10.3390/ijms222212346 URL
[21]	Cui QN, Stein LM, Fortin SM, et al. The role of glia in the physiology and pharmacology of glucagon-like peptide-1: Implications for obesity, diabetes, neurodegeneration and glaucoma[J]. Br J Pharmacol, 2022, 179(4):715-726. doi: 10.1111/bph.v179.4 URL
[22]	Manfready RA, Engen PA, Verhagen ML, et al. Attenuated postprandial GLP-1 response in parkinson's disease[J]. Front Neurosci, 2021, 2(15):660942.
[23]	郑鑫, 朱育刚, 王德峰. GLP-1受体激动剂对超重及肥胖2型糖尿病患者胰岛细胞功能影响的系统评价[J]. 临床荟萃, 2019, 34(12):1102-1107.
[24]	Zhang ZQ, Hölscher C. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models[J]. Peptides, 2020, 125:170184. doi: 10.1016/j.peptides.2019.170184 URL
[25]	Lv M, Xue G, Cheng H, et al. The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01[J]. Brain Behav, 2021, 11(8):e2231.
[26]	Chen X, Huang Q, Feng J, et al. GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway[J]. J Int Med Res, 2021, 49(2):300060521992981.
[27]	Jalewa J, Sharma MK, Gengler S, et al. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of parkinson's disease[J]. Neuropharmacology, 2017, 1(117):238-248.
[28]	Li T, Tu L, Gu R, et al. Neuroprotection of GLP-1/GIP receptor agonist via inhibition、of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model[J]. Life Sci, 2020, 1(256):117824.
[29]	Brauer R, Wei L, Ma T, et al. Diabetes medications and risk of parkinson's disease: A cohort study of patients with diabetes[J]. Brain, 2020, 143(10):3067-3076. doi: 10.1093/brain/awaa262 pmid: 33011770

胰高血糖素样肽-1在帕金森病“肠-脑轴”中的作用研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王九雪, 李娜, 靳玮, 王硕, 常雅君, 王天俊. 帕金森病患者血清尿酸、同型半胱氨酸和胱抑素C水平与运动症状及认知功能的相关性[J]. 临床荟萃, 2024, 39(2): 125-129.
[2]	张娜文, 黄少敏, 田利民. 2型糖尿病与帕金森病相关性研究的进展[J]. 临床荟萃, 2023, 38(9): 845-850.
[3]	王璐璐, 董露露, 江超, 王九雪, 常雅君, 王天俊. 弥散张量成像评估帕金森病合并非运动症状患者脑微结构的研究进展[J]. 临床荟萃, 2023, 38(2): 189-192.
[4]	孙亚南, 郝一峰, 李晓红. 肛门括约肌肌电图对多系统萎缩与帕金森病鉴别诊断价值的Meta分析[J]. 临床荟萃, 2022, 37(6): 490-496.
[5]	杨静静, 黄帅, 吴倩, 赵丽丽, 蒋影. 胰高血糖素样肽-1受体激动剂治疗肥胖的研究进展[J]. 临床荟萃, 2022, 37(5): 477-480.
[6]	王璐璐, 董露露, 王天俊. 多巴胺转运体^99mTc-TRODAT-1 SPECT显像在帕金森病诊断中的研究进展[J]. 临床荟萃, 2022, 37(5): 463-466.
[7]	郭畅, 沈慧楠, 孙艺萌, 王东玉. 血脂、同型半胱氨酸与帕金森病合并认知障碍相关性[J]. 临床荟萃, 2022, 37(2): 128-132.
[8]	李文君, 张策, 刘俊艳. 改善循环治疗加重帕金森病患者体位性低血压1例[J]. 临床荟萃, 2022, 37(10): 934-937.
[9]	但佳惠, 王相明, 张月辉. 磁共振成像对帕金森病诊断价值的研究进展[J]. 临床荟萃, 2021, 36(5): 476-480.
[10]	李蕾, 阿勒滕齐齐格, 张明琛, 蒋升. 胰高血糖素样肽-1受体激动剂治疗多囊卵巢综合征患者有效性与安全性的Meta分析[J]. 临床荟萃, 2021, 36(5): 395-401.
[11]	王亚平. 认知行为疗法对于帕金森病非运动症状的治疗进展[J]. 临床荟萃, 2020, 35(8): 766-768.
[12]	耿丽娟，刘晨菲，董慈，李冬，刘惠苗，顾平. 帕金森病患者昼夜节律失调性睡眠-觉醒障碍研究进展[J]. 临床荟萃, 2020, 35(8): 755-760.
[13]	刘姣1，王倩1,王东玉2. 曲唑酮对帕金森病患者情绪与睡眠质量的临床疗效[J]. 临床荟萃, 2020, 35(2): 153-157.
[14]	夏敏1，2，江一静1, 郑得忠1，2，王辉兴1，2，詹增土1，林志诚1. 体感游戏对帕金森病患者认知、步态的影响[J]. 临床荟萃, 2020, 35(10): 900-903.
[15]	方鹏洪，解冰川，马速，顾平. 帕金森病患者睡眠—觉醒障碍的临床表现及治疗进展[J]. 临床荟萃, 2019, 34(9): 855-860.